CanSino's Adenovirus COVID-19 Vaccine Shows Safety and Immune Response in Phase I Trial
A landmark Phase I trial of 108 adults tested the first adenovirus-vectored COVID-19 vaccine for safety and immune response.
Summary
In early 2020, as COVID-19 spread globally, CanSino Biologics launched one of the first Phase I clinical trials of a COVID-19 vaccine. The study enrolled 108 healthy adults aged 18 to 60 to evaluate the safety, tolerability, and immune response of a recombinant vaccine using an adenovirus type 5 vector to deliver the coronavirus antigen. This type of viral vector technology had previously been explored for other infectious diseases, making it a promising rapid-development platform. The trial was designed to establish a safety baseline before larger efficacy trials. Its completion marked a critical early milestone in the global race to develop COVID-19 vaccines and contributed foundational data on adenovirus-vectored vaccine platforms that influenced subsequent vaccine development worldwide.
Detailed Summary
When COVID-19 emerged from Hubei province, China in late 2019 and rapidly became a global pandemic, the absence of any proven antiviral therapy made vaccine development an urgent priority. CanSino Biologics launched this Phase I trial in March 2020, making it among the earliest formal vaccine safety studies against SARS-CoV-2.
The trial tested a Recombinant Novel Coronavirus Vaccine using an Adenovirus Type 5 (Ad5) vector — a viral vector platform designed to deliver coronavirus antigens and prompt the immune system to recognize and respond to the virus. One hundred and eight healthy adults between ages 18 and 60 were enrolled.
The primary goals, per the trial registration, were to assess safety, reactogenicity (how well the vaccine was tolerated), and immunogenicity (whether it triggered measurable immune responses). Phase I trials are not powered to demonstrate efficacy but are essential for establishing a safety profile before advancing to larger studies.
The trial completed enrollment of 108 participants and ran from March 2020 through February 2021. Results from Phase I trials of this kind typically inform decisions to advance to Phase II and III development, though specific outcome data are not contained in the registration record summarized here.
Several caveats apply. This summary is based solely on the trial registration record; full results including adverse event rates, antibody responses, and dose-response data are not available from this source. Additionally, the trial enrolled only adults aged 18–60, limiting generalizability to older adults and those with comorbidities who are most vulnerable to severe COVID-19.
Key Findings
- Phase I trial enrolled 108 healthy adults aged 18–60 to test an Ad5-vectored COVID-19 vaccine.
- Primary endpoints per the registration were safety, reactogenicity, and immunogenicity.
- The vaccine used an Adenovirus Type 5 (Ad5) viral vector platform.
- The trial ran from March 16, 2020 to February 20, 2021 and is listed as completed.
- This was among the earliest formal COVID-19 vaccine safety trials initiated globally in 2020.
Methodology
This was a Phase I clinical trial sponsored by CanSino Biologics Inc., enrolling 108 healthy adults aged 18–60. The study evaluated a recombinant adenovirus type 5 vectored COVID-19 vaccine, assessing safety, reactogenicity, and immunogenicity. The trial ran from March 2020 to February 2021 and is listed as completed. Specific dosing arms, blinding, and randomization details are not provided in the source abstract.
Study Limitations
This summary is based on the trial registration record only; full efficacy data, adverse event rates, and immunogenicity metrics are not available from this source. The trial enrolled only adults aged 18–60 and excluded those with underlying conditions, limiting generalizability to older or immunocompromised patients. As a Phase I study, it was not designed or powered to assess vaccine efficacy against COVID-19 infection.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.